China Huarong (2799 HK)'s Full Circulation
China Huarong Asset Management, which is expected to be in breach of Hong Kong's public float, is contemplating "full circulation" of some domestic...
525 Views
Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns
The article mainly analyzed Ark Biopharmaceutical in terms of the important product candidates AK0529 (ziresovir) and AK3280 that entered the...
520 Views
Pre-IPO Apollomics - Concerns on Competition and Commercialization Despite Some Promising Products
This article provided insights on its major products in the pipeline in terms of competitive landscape, strength and challenges, as well as...
942 Views
Full Circulation Of H-Shares: January 2021 Update
To date, 20 companies have sought approval to convert their domestic shares into H shares, 13 of which have now been given CSRC and Hong Kong...
696 Views
Full Circulation Of H-Shares - July Update
This update is the latest in a series dating back to Legend's Conversion of Domestic Shares in June 2018, with the most recent addition CPPCC And...
721 Views